Oric Pharmaceuticals (ORIC) Other Non-Current Liabilities (2020 - 2026)

Oric Pharmaceuticals (ORIC) has 7 years of Other Non-Current Liabilities data on file, last reported at $3.4 million in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 37.6% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (down 37.6% YoY) and the FY2025 annual result came in at $4.1 million, down 33.41% from the prior year.
• Other Non-Current Liabilities retreated to $3.4 million in Q1 2026, from $4.1 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $10.3 million in Q2 2022 to a low of $3.4 million in Q1 2026.
• A 5-year average of $7.2 million and a median of $7.0 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities jumped 4764.11% — and 2025, when it slumped 40.04%.
• Tracing ORIC's Other Non-Current Liabilities over 5 years: stood at $9.4 million in 2022, then decreased by 20.96% to $7.5 million in 2023, then declined by 17.25% to $6.2 million in 2024, then sank by 33.41% to $4.1 million in 2025, then dropped by 16.47% to $3.4 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $3.4 million (Q1 2026), $4.1 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.